ABBV vs SBUX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Starbucks Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Starbucks Corporation · Consumer Cyclical
$100.65
-6.1% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
SBUX trades at a lower forward P/E
(76.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
SBUX |
| Current Price |
$261.07 |
$100.65 |
| Fair Value Estimate |
$264.30 |
$94.50 |
| Upside to Fair Value |
+1.2%
|
-6.1%
|
| Market Cap |
$461.3B |
$114.7B |
| Forward P/E |
128.0x
|
76.7x
|
| EV / EBITDA |
31.0x
|
25.6x
|
| Price / Sales |
7.3x
|
3.0x
|
| Price / FCF |
22.1x
|
42.1x
|
| Revenue Growth YoY |
+12.4%
|
+8.8%
|
| Gross Margin |
70.7%
|
20.4%
|
| Operating Margin |
27.6%
|
9.3%
|
| Return on Equity |
68.0%
|
-18.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
2.38%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Starbucks Corporation operates a global coffeehouse chain with a strong brand and a leading digital/mobile platform, serving approximately 90 million customers weekly through over 28,000 stores in 77 countries. The company benefits from a durable competitive moat based on its extensive store footprint, brand recognition, and digital engagement rather than proprietary products. Despite solid reven…
Accumulation Zones
| Metric |
ABBV |
SBUX |
| Zone Low |
$198.23 |
$70.88 |
| Zone High |
$224.66 |
$80.33 |
| In Buy Zone? |
No
|
No
|